Zhong G.-C.,452 Hospital of People S Liberation Army |
Zhang X.-Y.,452 Hospital of People S Liberation Army |
Sum Y.,452 Hospital of People S Liberation Army |
Li S.,452 Hospital of People S Liberation Army |
And 4 more authors.
Tumor | Year: 2010
Objective: This study was to investigate the clinical efficacy and safety of autologous tumor cell lysate-pulsed dendritic cells (Ag-DCs) in combination with cytokine-induced killer (CIK) cells for lung adenocarcinomas. Methods: Peripheral blood mononuclear cells (PBMCs) were isolated from 30 patients with lung adenocarcinoma, and cultured with recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) and recombinant human interleukin 4 (rhIL-4) to induce dendritic cells (DCs). The DCs were pulsed with autologous tumor cell lysate. T lymphocytes from PBMC were incubated with interferon alpha (EFN-alpha) , IL-2, CD3 moAb, and EL-lα to induce CIK cells. The killing activity of CIK on lung adenocarcinoma A549 cells and autogenous tumor cells was investigated after CIK was co-cultured with Ag-DCs. The 30 patients received the immunotherapy with Ag-DCs and CIK. The immunologic and clinical responses were evaluated. Results: The killing activity of CIK cells on A549 and autologous tumor cells was increased remarkably after co-culture of CIK cells with Ag-DCs. Ag-DCs combined with CIK enhanced the immune function of lung adenocarcinoma patients, improved the living quality, and elevated the clinical efficacy. Except transient fever and chill, no remarkable adverse events were observed. Conclusion: Ag-DCs in combination with CIK cells was an effective adjuvant therapy for advanced lung adenocarcinomas.